Predicting risk for death from MRSA bacteremia

Emerging Infectious Diseases

Volumn 18, Issue 7, 2012, Pages 1072-1080

  Pastagia, Mina ^a   Kleinman, Lawrence C ^b   de la Cruz, Eliesel G Lacerda ^b   Jenkins, Stephen G ^c  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; HOST FACTOR; LINEZOLID; VANCOMYCIN;

ADULT; AGE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; CATHETER INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; FEMALE; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NURSING HOME PATIENT; PREDICTION; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SURVIVAL; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEW YORK CITY; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84862587173     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1807.101371     Document Type: Review

References (39)

1. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7:629-41. http://dx.doi.org/10.1038/nrmicro2200.
2. Finks J, Wells E, Dyke TL, Husain N, Plizga L, Heddurshetti R, et al. Vancomycin-resistant Staphylococcus aureus, Michigan, USA, 2007. Emerg Infect Dis. 2009;15:943-5. http://dx.doi.org/10.3201/eid1506.081312.
3. Lalani T, Boucher HW, Cosgrove SE, Fowler VG, Kanafani ZA, Vigliani GA, et al. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2008;61:177-82. http://dx.doi.org/10.1093/jac/dkm437.
4. Wunderink RG, Mendelson MH, Somero MS, Fabian TC, May AK, Bhattacharyya H, et al. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicil-lin-resistant Staphylococcus aureus. Chest. 2008;134:1200-7. http://dx.doi.org/10.1378/chest.08-0011
5. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358:207-8. http://dx.doi.org/10.1016/S0140-6736(01)05410-1.
6. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005;40:1058-60. http://dx.doi.org/10.1086/428616.
7. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60:788-94. http://dx.doi.org/10.1093/jac/dkm258.
8. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006;44:3883-6. http://dx.doi.org/10.1128/JCM.01388-06.
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S16. Wayne (PA): The Institute; 2006.
10. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42:2398-402. http://dx.doi.org/10.1128/JCM.42.6.2398-2402.2004.
11. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166:2138-44. http://dx.doi.org/10.1001/archinte.166.19.2138.
12. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:193-200. http://dx.doi.org/10.1086/524667.
13. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52:3315-20. http://dx.doi.org/10.1128/AAC.00113-08.
14. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38:448-51. http://dx.doi.org/10.1086/381093.
15. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis. 2009;199:619-24. http://dx.doi.org/10.1086/596629.
16. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis. 2006;42(Suppl 1):S13-24. http://dx.doi.org/10.1086/491710.
17. Velasco D, del Mar Tomas M, Cartelle M, Beceiro A, Perez A, Molina F, et al. Evaluation of different methods for detecting methicillin (oxacillin) resistance in Staphylococcus aureus. J Antimicrob Chemother. 2005;55:379-82. http://dx.doi.org/10.1093/jac/dki017.
18. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res. 1993;2:121-45. http://dx.doi.org/10.1177/096228029300200202.
19. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298:1763-71. http://dx.doi.org/10.1001/jama.298.15.1763.
20. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30:633-8. http://dx.doi.org/10.1086/313753.
21. SAS Institute. SAS 9.1 procedure user's manual. Cary (NC): The Institute, Inc; 2004.
22. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49:1373-9. http://dx.doi.org/10.1016/S0895-4356(96)00236-3.
23. Kleinman LC, Norton EC. What's the risk? A simple approach for estimating adjusted risk measures from nonlinear models including logistic regression. Health Serv Res. 2009;44:288-302. http://dx.doi.org/10.1111/j.1475-6773.2008.00900.x.
24. Musta AC, Riederer K, Shemes S, Chase P, Jose J, Johnson LB, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol. 2009;47:1640-4. http://dx.doi.org/10.1128/JCM.02135-08.
25. Horne KC, Howden BP, Grabsch EA, Graham M, Ward PB, Xie S, et al. Prospective comparison of the clinical impact of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (hVISA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother. 2009;53:3447-52. http://dx.doi.org/10.1128/AAC.01365-08.
26. Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC Jr, Eliopoulos GM. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J Infect Dis. 2009;199:532-6. http://dx.doi.org/10.1086/596511.
27. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol. 2008;46:2950-4. http://dx.doi.org/10.1128/JCM.00582-08.
28. Sun W, Chen H, Liu Y, Zhao C, Nichols WW, Chen M, et al. Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) from 14 cities in China. Antimicrob Agents Chemother. 2009;53:3642-9. http://dx.doi.org/10.1128/AAC.00206-09.
29. Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis. 2003;36:429-39. http://dx.doi.org/10.1086/346207.
30. Moise PA, Smyth DS, El-Fawal N, Robinson DA, Holden PN, Forrest A, et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2008;61:85-90. http://dx.doi.org/10.1093/jac/dkm445.
31. Mwangi MM, Wu SW, Zhou Y, Sieradzki K, de Lencastre H, Richardson P, et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A. 2007;104:9451-6. http://dx.doi.org/10.1073/pnas.0609839104.
32. Paul M, Kariv G, Goldberg E, Raskin M, Shaked H, Hazzan R, et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2010;65:2658-65. http://dx.doi.org/10.1093/jac/dkq373.
33. Schweizer ML, Furuno JP, Harris AD, Johnson JK, Shardell MD, McGregor JC, et al. Empiric antibiotic therapy for Staphylococcus aureus bacteremia may not reduce in-hospital mortality: a retrospective cohort study. PLoS ONE. 2010;5:e11432. http://dx.doi.org/10.1371/journal.pone.0011432.
34. Kaye KS, Anderson DJ, Choi Y, Link K, Thacker P, Sexton DJ. The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals. Clin Infect Dis. 2008;46:1568-77. http://dx.doi.org/10.1086/587673.
35. Rieg S, Peyerl-Hoffmann G, de With K, Theilacker C, Wagner D, Hubner J, et al. Mortality of S. aureus bacteremia and infectious diseases specialist consultation-a study of 521 patients in Germany. J Infect. 2009;59:232-9. http://dx.doi.org/10.1016/j.jinf.2009.07.015.
36. Lahey T, Shah R, Gittzus J, Schwartzman J, Kirkland K. Infectious diseases consultation lowers mortality from Staphylococcus aureus bacteremia. Medicine (Baltimore). 2009;88:263-7. http://dx.doi.org/10.1097/MD.0b013e3181b8fccb.
37. Sader HS, Rhomberg PR, Jones RN. Nine-hospital study compareing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53:3162-5. http://dx.doi.org/10.1128/AAC.00093-09.
38. Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol. 2001;39:2439-44. http://dx.doi.org/10.1128/JCM.39.7.2439-2444.2001.
39. Wootton M, MacGowan AP, Walsh TR, Howe RA. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol. 2007;45:329-32. http://dx.doi.org/10.1128/JCM.01508-06.